Teachers Retirement System of The State of Kentucky boosted its stake in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 47.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 362,550 shares of the biopharmaceutical company’s stock after purchasing an additional 116,800 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.18% of Incyte worth $43,996,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Fiduciary Financial Advisors bought a new position in shares of Incyte in the second quarter valued at about $26,000. Provenance Wealth Advisors LLC bought a new stake in shares of Incyte during the 3rd quarter worth about $33,000. Continuum Advisory LLC bought a new stake in shares of Incyte during the 2nd quarter worth about $36,000. Latitude Advisors LLC bought a new stake in shares of Incyte during the 3rd quarter worth about $39,000. Finally, Quantbot Technologies LP acquired a new position in Incyte in the 2nd quarter valued at about $52,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have weighed in on INCY shares. Citigroup reissued a “buy” rating on shares of Incyte in a report on Monday, August 3rd. Oppenheimer set a $152.00 price objective on shares of Incyte in a research report on Tuesday, October 27th. Stifel Nicolaus boosted their price objective on Incyte from $145.00 to $157.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Weiss Ratings downgraded Incyte from a “buy (b)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Finally, Mizuho increased their target price on Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Eleven equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $132.86.
View Our Latest Stock Report on INCY
Insiders Place Their Bets
In other news, CMO Steven H. Stein sold 240,193 shares of Incyte stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $118.39, for a total value of $28,436,449.27. Following the completion of the sale, the chief marketing officer directly owned 30,916 shares in the company, valued at approximately $3,660,145.24. The trade was a 88.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of Incyte stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the sale, the insider owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 254,246 shares of company stock worth $30,162,968 in the last quarter. Corporate insiders own 16.20% of the company’s stock.
Incyte Stock Performance
Shares of Incyte stock opened at $120.27 on Tuesday. The firm has a 50-day moving average of $119.05 and a 200-day moving average of $109.05. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60. The stock has a market cap of $24.51 billion, a PE ratio of 63.97, a PEG ratio of 4.43 and a beta of 0.78.
Incyte (NASDAQ:INCY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same period last year, the firm earned $2.26 earnings per share. Incyte’s revenue for the quarter was up 14.0% compared to the same quarter last year. Equities research analysts predict that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.
Incyte Company Profile
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
See Also
- Five stocks we like better than Incyte
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
